echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Phase II clinical trial of Golly Pharmaceuticals ASC40 for the treatment of acne was approved by the State Food and Drug Administration

    The Phase II clinical trial of Golly Pharmaceuticals ASC40 for the treatment of acne was approved by the State Food and Drug Administration

    • Last Update: 2021-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 9, Golly Pharmaceuticals announced that China's National Medical Products Administration has approved the launch of ASC40 in the treatment of patients with moderate and severe acne phase II clinical trials


    The Phase II study is a randomized, double-blind, placebo-controlled, multi-center clinical trial to be carried out in China to evaluate the safety and effectiveness of each dose group in the treatment of patients with moderate and severe acne vulgaris


    Acne is the eighth most epidemic disease in the world, and the number of acne patients worldwide exceeds 640 million


    The current first-line drugs for acne treatment include topical creams such as retinoic acid, androgen receptor inhibitors, oral isotretinoin and antibiotics


    Fatty acid synthase (FASN) is a key enzyme in the pathway of regulating fatty acid de novo synthesis (DNL)


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.